Company Overview of Alliqua BioMedical, Inc., Prior To Merger With Alliqua, Inc.
As of June 5, 2014, Alliqua BioMedical, Inc was acquired by Alliqua, Inc. Alliqua BioMedical, Inc. develops, manufactures and markets ingredient and transdermal drug delivery products. The company is based in New York, New York. Alliqua BioMedical, Inc. operates as a subsidiary of Alliqua, Inc.
850 3rd Avenue
New York, NY 10022
Key Executives for Alliqua BioMedical, Inc., Prior To Merger With Alliqua, Inc.
Alliqua BioMedical, Inc., Prior To Merger With Alliqua, Inc. does not have any Key Executives recorded.
Alliqua BioMedical, Inc., Prior To Merger With Alliqua, Inc. Key Developments
James Sapirstein Resigns as Chief Executive Officer of Alliqua Biomedical, Inc
Mar 19 14
On March 14, 2014, James Sapirstein resigned as chief executive officer of Alliqua Biomedical, Inc, effective immediately.
Alliqua Biomedical, Inc. Enters into Distributor Agreement with Sorbion GmbH & Co KG
Sep 26 13
Alliqua Biomedical, Inc., a wholly-owned subsidiary of Alliqua, Inc., entered into a distributor agreement with Sorbion GmbH & Co KG, pursuant to which the company became the exclusive distributor of sorbion sachet S, sorbion sana and new products with hydrokinetic fibers as primary dressings in the United States of America, Canada and Latin America, subject to certain exceptions. The initial term of the Sorbion Agreement ends on December 31, 2018, unless sooner terminated pursuant to the termination rights under the Sorbion Agreement, and will be extended for additional year terms until December 31, 2023, so long as the company and Sorbion agree in September as to the minimum annual purchase amount for the calendar year that ends four years from the calendar year of such September, such that, for example, in September 2014, the company and Sorbion must agree to the minimum annual purchase amount for the 2018 calendar year so that the Sorbion Agreement is extended until December 31, 2019. The company may terminate the Sorbion Agreement upon six months prior written notice to Sorbion. Sorbion may terminate the Sorbion Agreement for good cause, which shall include the company's application for insolvency proceedings, a change of control of the company that may disrupt the company's relationship with Sorbion, the company's failure to cure a material breach of the Sorbion Agreement within 60 days or the company's challenge of Sorbion's intellectual property.
Alliqua, Inc. Names James Sapirstein as Chief Executive Officer of Alliqua Biomedical, Inc
Feb 7 13
On February 5, 2013, announced a strategic realignment of the senior executive team. This change is designed to strengthen the leadership of the company’s differentiated businesses including the sales of Alliqua’s marketed brands, SilverSeal and Hydress. The Alliqua Board of Directors has approved David Johnson, who joined the Board in December of 2012 and is currently the executive chairman of AquaMed Technologies, to now assume the additional responsibility of chief executive officer of Alliqua, Inc. Concurrently, James Sapirstein will become the chief executive officer of Alliqua BioMedical, Inc., a wholly-owned subsidiary of the company.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|